Solvonis Advances PTSD Treatment Program with New Candidate Synthesis

An announcement from Graft Polymer (UK) PLC ( (GB:SVNS) ) is now available.

Solvonis Therapeutics plc has completed the synthesis of development candidates for its SVN-SDN-014 program, which is focused on creating a new class of medicines for PTSD. This marks the third stage of their seven-stage translational development plan, aiming to improve safety profiles and enhance pro-social behavior in PTSD patients. The program’s progress underscores Solvonis’s commitment to addressing significant clinical needs in mental health, with further stages including in-vitro screenings and pre-clinical animal testing anticipated to advance the program towards regulatory submission.

More about Graft Polymer (UK) PLC

Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company based in London, focusing on developing novel medicines for addiction and mental health disorders. Listed on the London Stock Exchange, Solvonis targets high-burden neuropsychiatric conditions with significant unmet needs, including Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD). The company employs a capital-efficient model and dual development strategy to advance its pipeline of repurposed and novel compounds.

Average Trading Volume: 17,909,326

Technical Sentiment Signal: Sell

Current Market Cap: £7.68M

Find detailed analytics on SVNS stock on TipRanks’ Stock Analysis page.